18.79
-0.17 (-0.90%)
| Previous Close | 18.96 |
| Open | 18.83 |
| Volume | 957,909 |
| Avg. Volume (3M) | 2,316,078 |
| Market Cap | 3,470,317,056 |
| Price / Earnings (Forward) | 44.05 |
| Price / Sales | 4.20 |
| Price / Book | 3.79 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Legend Biotech Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.50 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 47.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Westfield Capital Management Co Lp | 30 Sep 2025 | 6,094,486 |
| Hhlr Advisors, Ltd. | 30 Sep 2025 | 5,984,550 |
| Suvretta Capital Management, Llc | 30 Sep 2025 | 3,818,009 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 2,962,338 |
| Artisan Partners Limited Partnership | 30 Sep 2025 | 2,547,952 |
| Braidwell Lp | 30 Sep 2025 | 1,826,155 |
| Matthews International Capital Management Llc | 30 Sep 2025 | 1,028,447 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Barclays, 378.98%) | Buy |
| Median | 58.00 (208.68%) | |
| Low | 21.00 (TD Cowen, 11.76%) | Hold |
| Average | 59.25 (215.33%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 23.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Jan 2026 | 50.00 (166.10%) | Buy | 19.34 |
| TD Cowen | 22 Jan 2026 | 21.00 (11.76%) | Hold | 19.34 |
| RBC Capital | 20 Jan 2026 | 66.00 (251.25%) | Buy | 23.42 |
| 13 Nov 2025 | 74.00 (293.83%) | Buy | 31.01 | |
| Oppenheimer | 07 Jan 2026 | 75.00 (299.15%) | Buy | 22.72 |
| Cantor Fitzgerald | 17 Dec 2025 | 74.00 (293.83%) | Buy | 21.42 |
| 13 Nov 2025 | 75.00 (299.15%) | Buy | 31.01 | |
| Morgan Stanley | 12 Dec 2025 | 50.00 (166.10%) | Buy | 22.32 |
| UBS | 08 Dec 2025 | 48.00 (155.46%) | Buy | 26.12 |
| Barclays | 13 Nov 2025 | 90.00 (378.98%) | Buy | 31.01 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |